Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window

Stock News

Cardinal Health’s Stock Ascends: Buying Opportunity?

Timothy SykesAvatar
Written by Timothy Sykes
Updated 6/12/2025, 2:32 pm ET 8 min read

Cardinal Health Inc.’s stock has been trading up by 4.48 percent following a new breakthrough in medical supplies.

Pressured Boosting: Cardinals Health’s Key Moves

  • Anticipation soars as Cardinal Health updates long-term financial goals during Investor Day, boosting stock price and investor confidence.
  • Recent upgrades include Bank of America’s price target increase to $170, maintaining a ‘Buy’ recommendation amidst positive forecasts for earnings per share growth.
  • Mizuho and Evercore ISI have both raised their price targets, indicating strong market confidence in Cardiinal Health’s future performance.

Candlestick Chart

Live Update At 14:32:24 EST: On Thursday, June 12, 2025 Cardinal Health Inc. stock [NYSE: CAH] is trending up by 4.48%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Overview: Financial Highlights and Strategic Decisions

In the fast-paced world of trading, one of the key strategies for success is being flexible and open to change. As millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.” This means understanding market trends and adjusting trading strategies accordingly. By doing so, traders can better position themselves to seize opportunities and avoid potential pitfalls, ensuring they remain competitive and effective in an ever-evolving industry.

Cardinal Health has certainly kept investors on their toes! Imagine watching as a gymnast sticks a landing – that’s what the recent market response to Cardinal Health’s strategies feels like. The commitment to sustainable growth in its earnings per share (EPS) speaks volumes about their forward-thinking approach. With BofA and Mizuho raising their price targets, investor confidence seems to be rising like a tide lifting all boats.

With an operating revenue reported at nearly $54.88B and a net income of $506M, the figures underline a robust financial footing. Revenues are outpacing total expenses, hinting at a careful yet aggressive strategy anchored in solid operational performance. The company reported a gross profit of $2.12B, which substantiates its growing standing in the pharmaceutical sector.

Debt, as always, is a double-edged sword. Cardinal Health has managed debt carefully, with long-term debt at approximately $7.14B. Additionally, their cash flow from continuing operations stands strong at $2.92B. Though the total assets dwarf total equity, the reliance and effective use of debt hint at a daring but smart financial game plan.

More Breaking News

Revenue trends over the last years show consistent growth, and with a PE ratio of 23.99, they are nestled comfortably within industry standards. However, their price-to-book value, skewed toward the negative, might send cautionary ripples to those relying heavily on this metric alone.

Market Performance and Stock Activity

The stock market can sometimes feel like a roller-coaster, leaving some with white knuckles and others begging for more. As of June 12, 2025, Cardinal Health’s stock opened at $155.10, peaked at $160.71, and closed slightly below the high at $160.45. This represents a noticeable upward wiggle in their journey, likely fueled by recent announcements and raised price targets from prominent analysts.

The meticulous dance between volume and price displayed on the June 11 trading chart offers insights into market sentiment. With analysts increasing price targets and investor enthusiasm visibly awakening, this translates into bullish vibes across the stock’s ticker. Morning announcements and price target hikes injected vitality into the market, and investors watched closely as the dance unfolded.

Amidst trading, stocks sometimes behave like highly-caffeinated toasters – popping up surprisingly high, beyond what many anticipate. With this latest boost in stock prices, readers might wonder if there is room left for another stride forward. This is where understanding the intricacies from fundamental financial reports to current pricing and trading metrics becomes indispensable for investors.

Innovation in Medical Device and Market Expansion

In another unfurled storyline, Cardinal Health unfurled its new product: the Kendall DL™ Multi System. Sleek, and quite the convenient contraption, it provides seamless monitoring of cardiac activity, blood oxygen, and temperature in one point of connection. Not only does it promise enhanced patient care, but sporadic sparks of interest light the path toward improved financial performance for healthcare providers.

A nifty device for sure, poised to meet the needs of both patients and providers by efficiently maneuvering through points of patient engagement from admission to discharge. This innovation speaks volumes about Cardinal Health’s commitment to technological advancement in healthcare.

Evaluating Stock Surge: Long-Term Reverberations

From a distance, stock surges can appear something like a volcano, with every investor eyeing the horizon for tremors. Cardinal Health’s potential gains look set to sway market dynamics positively. While the numbers hint at an appealing destination, one must bridle enthusiasm with caution when riding the capricious waves of Wall Street.

The financial reports showcase an intriguing picture of their asset management, pivotal decisions about debt, strategic alliances, and dividends that echo well-thought-out financial moves. Yet, as the stock ticks upwards, potential investors might weigh whether the growth emanates from a genuine expansion or perhaps an overzealous market fervor.

Future forecasts remain foggy yet hopeful. Analysts see sustained overarching growth, shading an optimistic hue over what lays ahead. Yet, the apron strings of fiscal responsibility tugging at Cardinal Health become key determinants to the genuine longevity and pace of this bright upward journey.

While the word ‘bubble’ bounces in some conversations, Cardinal Health’s strategic moves – from product innovation to market positioning – are expected to bolster its position against unexpected market gusts. However, with the buoyant numbers coming out of major financial institutions, a new question arises: Are we witnessing sustainable growth or merely a momentary blip in the stock pricing matrix?

Market Influence: Predictions and Potential

As investors mull over their options, the bigger question remains: Will Cardinal Health continue to unravel its successes, shaping a future lined with optimism, or will it stumble over growth hurdles left unaddressed? The puzzle of investing continuously revolves around balancing enthusiasm against judicious analysis.

Amidst the noise, the calm voice that suggests a stable, gradual rise rings clear. Recent affirmative notes from high-profile analysts blend into the narrative of Cardinal Health as an evolving giant. The narrative unfolds as more than just a cautionary tale, bridging facts with expectations and examining how this powerhouse might perform in the ever-changing market theater.

Conclusion: Previous Strategies and Future Implications

Now, as we fold away the pages of this intriguing tale, traders may reflect on how the arcs of growth blend seamlessly with the pursuit of financial stability. With the score of updates from Cardinal Health whispering promises of sustainable growth, the panorama ahead is captivatingly enigmatic yet hopeful. As millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.”

So, as readers navigate this labyrinth of numbers and market sentiments, they gain the tools to discern their inclinations, recognizing when opportunity rings or when caution whispers. And thus, the story of Cardinal Health – from innovations to upgraded expectations – continues to write its chapters in the books of market dominance and financial resilience.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:


How much has this post helped you?



Leave a reply

Author card Timothy Sykes picture

Timothy Sykes

Tim Sykes is a penny stock trader and teacher who became a self-made millionaire by the age of 22 by trading $12,415 of bar mitzvah money. After becoming disenchanted with the hedge fund world, he established the Tim Sykes Trading Challenge to teach aspiring traders how to follow his trading strategies. He’s been featured in a variety of media outlets including CNN, Larry King, Steve Harvey, Forbes, Men’s Journal, and more. He’s also an active philanthropist and environmental activist, a co-founder of Karmagawa, and has donated millions of dollars to charity.
Read More


* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM
notification icon
Subscribe to receive notifications